Actual Medicinal Product (AMP) Ambrisentan 10mg tablets (Cipla EU Ltd)

Stability Information

(Some stability information inherited from generic)

Stability
compatible logo Suitable for use in MCAs, although use is likely to be off-label. Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or up to 8 weeks if the MCA is airtight (sealed). Consider the risk of potency loss or dose variability and monitor for changes in efficacy or adverse effects after MCA initiation.
Notes

No stability data in MCAs available but no theoretical concerns with product.

Provenance

This recommendation is based on the product Volibris 10mg film coated tablets (GlaxoSmithKline UK) and  Ambrisentan 10mg film-coated Tablets (Cipla EU Ltd).

Generic
Ambrisentan
Formulation
Ambrisentan 10mg tablets
  • Ambrisentan
    • Ambrisentan 10mg tablets

      • Ambrisentan 10mg tablets (Cipla EU Ltd)